Life Biosciences' ER 100 uses three reprogramming genes, called the Yamanaka factors, to coax aged optic nerve cells back toward a youthful state in a Phase 1 safety test for glaucoma.
On 9 June 2026, a Boston biotech named Life Biosciences announced it had treated the first human patient with ER-100, a gene therapy that attempts to do something medicine has not tried in a person before: turn back the biological clock of damaged optic-nerve cells so they can regenerate the way they did in youth.
The patient has open-angle glaucoma and is the first of up to twelve participants Life Bio plans to enroll in a Phase 1 trial registered on ClinicalTrials.gov as NCT07290244. The trial's primary endpoint is safety, not vision improvement. Regulators at the FDA cleared the company's application to begin human studies in late January 2026, according to the Life Biosciences press release of 9 June 2026.
The mechanism is a controlled version of "partial cellular reprogramming," a technique that has, until now, lived entirely in laboratory animals. ER-100 uses a modified virus to deliver three genes, called the Yamanaka factors (Oct4, Sox2, and Klf4), to the retinal ganglion cells that wire the eye to the brain. The three genes are switched on by the antibiotic doxycycline and stop working when the drug is withdrawn. In theory, the on-off switch nudges an old, damaged cell partway back toward a youthful state without erasing what type of cell it is, letting it regrow the connection it has lost.
The eye is a deliberate choice. As Heidi Ledford reported for Nature, independent researchers see it as a sensible place to test a powerful but unproven technology, because a contained organ limits the damage if something goes wrong. The preclinical evidence comes from a 2020 study from David Sinclair's lab at Harvard Medical School, published in Nature, which showed that activating the same three genes in mice with damaged optic nerves regrew retinal ganglion cells and reversed vision loss in both aged and glaucomatous animals. Life Bio says it has since repeated the work in nonhuman primates without serious adverse effects.
But the same biology that makes the approach appealing is also what worries safety reviewers. The Yamanaka factors are best known for their ability to turn ordinary adult cells into stem cells, and in some contexts that same flexibility can push a cell toward becoming cancerous. Matt Kaeberlein, a geroscientist who runs Optispan in Seattle, told Scientific American that the technology is early and the potential for catastrophic side effects is high. He supports the decision to test it in the eye first, where a tumor would not be immediately life-threatening, but said the broader field will be watching for off-target effects.
Pete Williams, who studies optic-nerve regeneration at the Centre for Eye Research Australia in Melbourne, is more hopeful. He called the trial a welcome new strategy for a class of damage that has no proven treatment, while warning that a public failure could chill investment in similar approaches for years.
Life Bio's chief scientific officer, Sharon Rosenzweig-Lipson, has been careful to limit the company's claims. "We're not looking at whole-body rejuvenation at this point in time," she told Scientific American. The company frames ER-100 as a disease-modifying therapy for optic neuropathies, not as a general anti-aging product. A second cohort, for non-arteritic anterior ischemic optic neuropathy (NAION), is planned to follow the glaucoma group.
The first read of the trial will be whether the gene therapy, and the doxycycline switch that controls it, are tolerable in a human eye at all. The longer read is whether regenerated cells actually wire back into the brain in a way that restores usable vision. If either answer comes back positive, the same platform, and there are several in academic and commercial pipelines, is likely to be tested in organs where age-related cell loss is more life-altering than blindness in one eye.